Market Closed - Nasdaq Copenhagen 15:59:58 17/05/2024 BST 5-day change 1st Jan Change
2,041 DKK +0.74% Intraday chart for Genmab A/S +1.90% -5.29%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation' MT
Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50% MT
Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association Congress CI
GENMAB : A good start to 2024; guidance unchanged Alphavalue
Genmab Posts Q1 Net Profit Surge; Revenue Jumps MT
Genmab Reports Higher Interim Q1 Results; Maintains 2024 Guidance MT
Transcript : Genmab A/S, Q1 2024 Earnings Call, May 02, 2024
Genmab A/S Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer MT
Genmab, Pfizer Win US FDA Approval for Cervical Cancer Treatment MT
Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer CI
Pfizer, Genmab Get Full FDA Approval for Cervical-Cancer Drug DJ
Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug MT
Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024 CI
Health Care Slips on Risk Bias -- Health Care Roundup DJ
Health Care Flat on Rotation to Rate-Sensitive Sectors -- Health Care Roundup DJ
News Highlights : Top Company News of the Day - Wednesday at 11 AM ET DJ
Global markets live: Swiss Re, Intel, Walt Disney, Paramount, Microsoft... Our Logo
News Highlights : Top Company News of the Day - Wednesday at 9 AM ET DJ
Correction to Genmab Article DJ
Genmab: acquisition of ProfoundBio greeted without emotion CF
News Highlights : Top Company News of the Day - Wednesday at 7 AM ET DJ
Genmab A/S Re-Affirms Revenue Guidance for the Year 2024 CI
Transcript : Genmab A/S, ProfoundBio - M&A Call
European Midday Briefing : Stocks Continue to Struggle Despite Cooling Inflation DJ
Chart Genmab A/S
More charts
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.2%); - income from research and development (12.4%); - other (4.4%): primarily income from partnership agreement. At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Denmark accounts for all net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
2,041 DKK
Average target price
2,470 DKK
Spread / Average Target
+21.01%
Consensus
  1. Stock Market
  2. Equities
  3. GMAB Stock
  4. News Genmab A/S
  5. Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug